Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: TWYNSTA

« Back to Dashboard
Twynsta is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

The generic ingredient in TWYNSTA is amlodipine besylate; telmisartan. There are fourty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amlodipine besylate; telmisartan profile page.

Summary for Tradename: TWYNSTA

Suppliers: see list1

Clinical Trials for: TWYNSTA

A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
Status: Recruiting Condition: Hypertension

Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
Status: Completed Condition: Hypertension

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
Status: Completed Condition: Hypertension

ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)
Status: Recruiting Condition: Hypertension and Atrial Fibrillation

The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers
Status: Enrolling by invitation Condition: Healthy Male Volunteer

Telmisartan, Amlodipine and Flow Mediated Dilation
Status: Active, not recruiting Condition: Hypertension

Telmisartan 80mg Non-responder Trial
Status: Completed Condition: Hypertension

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
Status: Completed Condition: Healthy

Telmisartan and Amlodipine Versus Monocomponent Tablets
Status: Completed Condition: Hypertension

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
Status: Completed Condition: Hypertension

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
amlodipine besylate; telmisartan
TABLET;ORAL022401Oct 16, 2009RXNo5,591,762<disabled>YY<disabled>
Boehringer Ingelheim
amlodipine besylate; telmisartan
TABLET;ORAL022401Oct 16, 2009RXYes5,591,762<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn